Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASSURE HOLDINGS CORP.

(IONM)
  Report
Delayed Nasdaq  -  02:21 2022-10-05 pm EDT
0.6900 USD   -4.17%
09/29Assure to Attend Investor Conferences in October 2022
AQ
09/07Assure Holdings Corp. : Other Events (form 8-K)
AQ
09/07Benchmark Company Lowers Assure Holdings' Price Target to $4 From $6, Maintains Speculative Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Assure : Reports Second Quarter 2022 Financial Results - Form 8-K

08/15/2022 | 05:59pm EDT

Assure Holdings Reports Second Quarter 2022 Financial Results

Second quarter 2022 managed case volume increased by approximately 36% year-over-year
Managed case volume expected to grow by approximately 30% in the second half of the year compared with the first half of 2022 and more than 40% in full year 2022
Company expects to achieve positive Adjusted EBITDA in the second half of 2022
Assure took a more conservative approach to 2020 accounts receivable, recognizing $7.6 million in accounts receivable reserve netted against $9.2 million in gross revenue; reducing expected second-half total accounts receivable reserve accrual to less than $4.0 million over the 6-month period

DENVER, August 15, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the "Company" or "Assure") (NASDAQ: IONM), a provider of intraoperative neuromonitoring ("IONM") and remote neurology services, reported financial results for the second quarter ended June 30, 2022.

Key Financial Metrics (in thousands of USD)

2Q'22

2Q'21

Gross Revenue

$ 9,209

$ 7,320

Accounts Receivable Reserve

(7,564)

(1,100)

Revenue, net

1,645

6,220

Gross Profit

(2,357)

3,050

Total Operating Expenses

4,094

4,516

Adjusted EBITDA

(5,912)

(877)

*- See Explanation of Non-GAAP Financial Measures below for an explanation of Adjusted EBITDA and a reconciliation to GAAP financial measures

Key Operational Metrics

2Q'22

2Q'21

Remote Neurology Managed Cases

1,900

-

Total Managed Cases

5,800

4,300

* Remote neurology managed cases began in 3Q'21

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

Second Quarter 2022 Financial Summary vs. Second Quarter 2021

Managed cases increased by approximately 36% to 5,800
Gross revenue prior to accounts receivable reserve was $9.2 million
Net revenue was $1.6 million versus $6.2 million
Adjusted EBITDA was ($5.9) million versus ($0.9) million
Net loss of ($4.7) million versus ($1.3) million
Net loss per diluted share of ($0.37) versus ($0.11)
General and administrative expenses were $3.6 million compared to $4.0 million
Total cash collected was a record $7.7 million versus $6.0 million
Cash collected on Assure-owned professional and technical services entities was a record $6.0 million versus $3.8 million
Assure is collecting more than 65% on receivables from the first 6 months after they were issued and more than 85% in first 12 months after they were issued for Company's 100% owned professional and technical entities, both representing record amounts

See "Explanation of Non-GAAP Financial Measures" below for an explanation of Adjusted EBITDA and a reconciliation to GAAP financial measures

Management Commentary

"Our second-quarter and first-half performance laid the groundwork for what we believe will be a significantly stronger, more financially stable second half of 2022 and beyond for Assure," said John A. Farlinger, Assure's executive chairman and CEO. "Assure outperformed in managed case volume and cash collections, underscoring the growth and strength of our business. We have also taken steps to become leaner and profitable. Given recent economic and capital markets uncertainty, Assure began a strategic cost-reduction effort that we expect will yield over $4.5 million of annualized savings. As a result, we expect to become cash flow positive on an adjusted operating basis in the second half of 2022. What's more, we chose to take a more conservative stance in our assessment of the outstanding 2020 accounts receivable maturing during the second half of 2022 to provide clearer visibility into future write-down expenses. As a result, the Company reduced its anticipated second-half reserve exposure to less than $4 million. Lastly, the health care collections disruption experienced in 2020 associated with the onset of COVID-19 was a highly unusual situation. A regulation change has extended the timeline to pursue these receivables and we expect to recover some of the accounts receivable reserve in the coming quarters."

"Therefore, I believe Assure's second-half performance will continue to reveal the underlying strength of the business and the sustained improvement in collections of newer claims. We anticipate positive Adjusted EBITDA in the second half of 2022 as well, anchored by strong revenue growth, managed case volume expansion, our ramping remote neurology platform and stable accrual rates in our key high-volume markets," concluded Farlinger.

Assure has filed its quarterly financial statements on Form 10-Q with the SEC at www.sec.govand on the Company website.

Operational and Financial Guidance

The Company is forecasting more than 25,000 total managed cases for fiscal year 2022, a record number of managed cases, and an increase of more than 40% compared with 2021 volume.

In the second half of 2022, Assure is forecasting:

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

Gross revenue of greater than $22 million
Accounts receivable reserve expense of less than $4 million
Adjusted EBITDA of greater than $2 million

Conference Call

The Company will hold a conference call today, August 15, 2022, at 4:30 p.m. Eastern Time to discuss its second quarter 2022 results.

The live webcast of the conference call and related presentation slides can be accessed at ir.assureneuromonitoring.com/news-events/ir-calendar. An audio-only option is available by following the dial-in instructions below. Investors who opt for audio-only will need to download the related slides at ir.assureneuromonitoring.com/company-information/presentations.

Date: Monday, August 15, 2022
Time: 4:30 p.m. Eastern Time (2:30 p.m. Mountain Time)
Toll-free dial-in number: 1-866-374-4635
International dial-in number: 1-412-542-4150
Conference ID: 10170318

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay here.

A replay of the conference call will be available after 7:30 p.m. Eastern Time on the same day through August 29, 2022.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 10170318

Explanation of Non-GAAP Financial Measures

This press release includes certain measures which have not been prepared in accordance with Generally Accepted Accounting Principles ("GAAP") such as Adjusted EBITDA. We define EBITDA as net income/(loss) before interest expense, provision for income taxes, depreciation and amortization. We calculate Adjusted EBITDA as EBITDA further adjusted to exclude the effects of the following items: share-based compensation, gain on payroll protection program loan and gain on extinguishment of acquisition debt. We exclude share-based compensation because this represents a non-cash charge and our mix of cash and share-based compensation may differ from other companies, which effects the comparability of results of operations and liquidity. We exclude gain on payroll protection program loan and gain on extinguishment of acquisition debt because these are non-recurring items, and we believe their inclusion is not representative of operating performance. Adjusted EBITDA is not an earnings measure recognized by GAAP and does not have a standardized meaning prescribed by GAAP. Management believes that Adjusted EBITDA is an appropriate measure in evaluating the Company's operating performance. Management uses Adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. Management believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. Readers are

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

cautioned that Adjusted EBITDA should not be construed as an alternative to net income (as determined under GAAP), as an indicator of financial performance or to cash flow from operating activities (as determined under GAAP) or as a measure of liquidity and cash flow. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. We attempt to compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures presented below and not rely on any single financial measure to evaluate our business.

Key Performance Metrics

This announcement contains key performance metrics that management of the Company utilizes to determine operational performance from period to period. These metrics include managed cases and remote neurology managed cases. We define managed cases as all technical cases Assure performs and any cases where the professional bill is from a 100% owned Assure entity and excludes cases when a global bill is presented and we calculate it based on bills presented during the relevant measurement period. We define remote neurology managed cases as a subset of managed cases where Assure's remote neurology platform is utilized and billed. Management believes that managed cases and remote neurology managed cases are important measures of the Company's operational performance because they are a consistent measurement to evaluate patient revenue streams.

About Assure Holdings

Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients' neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure's mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company's website at www.assureneuromonitoring.com.

Forward-Looking Statements

This news release may contain "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. Forward-looking statements include, but are not limited to, management's expectation of continued improvement in revenue and profitability, continued increases in managed cases, stable accrual rates and our ramping remote neurology platform, potential savings for the strategic cost-reduction efforts, our expectation of becoming cash flow positive on an adjusted operating basis in the second half of 2022, that our second-half performance will continue to reveal the underlying strength of the business, that we will have sustained improvement in collections of newer claims, our expectation of having positive Adjusted EBITDA in the second half of 2022. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include risks regarding our patient volume or cases not growing as expected, or decreasing, which could impact revenue and profitability; unfavorable economic conditions could have an adverse effect on our business; risks related to increased leverage resulting from

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

incurring additional debt; the policies of health insurance carriers may affect the amount of revenue we receive; our ability to successfully market and sell our products and services; we may be subject to competition and technological risk which may impact the price and amount of services we can sell and the nature of services we can provide; regulatory changes that are unfavorable in the states where our operations are conducted or concentrated; our ability to comply and the cost of compliance with extensive existing regulation and any changes or amendments thereto; changes within the medical industry and third-party reimbursement policies and our estimates of associated timing and costs with the same; our ability to adequately forecast expansion and the Company's management of anticipated growth; and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the United States Securities and Exchange Commission, including our annual report on Form 10-K filed on March 14, 2022, and with the Canadian securities regulators and available on the Company's profiles on EDGAR at www.sec.gov and SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
Scott.Kozak@assureiom.com

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

SCHEDULE A

ASSURE HOLDINGS CORP.

CONSOLIDATED BALANCE SHEETS

(in thousands of Dollars)

June 30,

December 31,

2021

2021

(unaudited)

ASSETS

Current assets

Cash

$

792

$

4,020

Accounts receivable, net

20,989

27,810

Income tax receivable

157

136

Other current assets

357

151

Due from MSAs

6,591

5,886

Total current assets

28,886

38,003

Equity method investments

484

525

Fixed assets

55

85

Operating lease right of use asset

779

956

Finance lease right of use asset

579

743

Deferred tax asset, net

2,039

-

Intangibles, net

3,424

3,649

Goodwill

4,448

4,448

Total assets

$

40,694

$

48,409

LIABILITIES AND SHAREHOLDERS' EQUITY

LIABILITIES

Current liabilities

Accounts payable and accrued liabilities

$

3,376

$

2,194

Current portion of debt

-

515

Current portion of lease liability

679

702

Current portion of acquisition liability

306

306

Total current liabilities

4,361

3,717

Lease liability, net of current portion

1,236

1,482

Debt, net of current portion

12,418

13,169

Acquisition liability

332

459

Fair value of stock option liability

-

25

Deferred tax liability, net

-

601

Total liabilities

18,347

19,453

SHAREHOLDERS' EQUITY

Common stock

13

13

Additional paid-in capital

43,963

43,387

Accumulated deficit

(21,629)

(14,444)

Total shareholders' equity

22,347

28,956

Total liabilities and shareholders' equity

$

40,694

$

48,409

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

ASSURE HOLDINGS CORP.

CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands of Dollars, except per share amounts)

(unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2022

2021

2022

2021

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Revenue

Technical services

$

67

$

4,095

$

1,463

$

7,228

Professional services

854

652

3,327

966

Other

724

1,473

1,556

2,791

Total revenue

1,645

6,220

6,346

10,985

Cost of revenues

4,002

3,170

7,879

5,702

Gross margin

(2,357)

3,050

(1,533)

5,283

Operating expenses

General and administrative

3,596

3,963

7,837

7,095

Sales and marketing

238

166

490

501

Depreciation and amortization

260

387

518

672

Total operating expenses

4,094

4,516

8,845

8,268

Loss from operations

(6,451)

(1,466)

(10,378)

(2,985)

Other income (expenses)

Income (loss) from equity method investments

4

20

9

(3)

Gain on Paycheck Protection Program loan forgiveness

-

-

1,665

-

Other income (expense), net

28

1

66

(2)

Accretion expense

(171)

(120)

(341)

(215)

Interest expense, net

(439)

(218)

(846)

(236)

Total other expense

(578)

(317)

553

(456)

Loss before income taxes

(7,029)

(1,783)

(9,825)

(3,441)

Income tax benefit

2,303

474

2,640

901

Net loss

$

(4,726)

$

(1,309)

$

(7,185)

$

(2,540)

Loss per share

Basic

$

(0.37)

$

(0.11)

$

(0.56)

$

(0.22)

Diluted

$

(0.37)

$

(0.11)

$

(0.56)

$

(0.22)

Weighted average number of shares used in per share calculation - basic

12,919,666

11,589,857

12,919,546

11,400,471

Weighted average number of shares used in per share calculation - diluted

12,919,666

11,589,857

12,919,546

11,400,471

7887 E. Belleview Ave

Suite 500

Greenwood Village, CO 80111

(720)287-3093

ASSURE HOLDINGS CORP.

RECONCILIATION OF NON-GAAP ADJUSTED EBITDA TO NET LOSS

(in thousands of Dollars)

(unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2021

2021

2022

2021

(unaudited)

(unaudited)

(unaudited)

(unaudited)

EBITDA

Net Income (loss)

($ 4,726)

($ 1,309)

($ 7,185)

($ 2,540)

Interest expense

439

218

846

236

Accretion expense

171

120

341

215

Income tax

(2,303)

(474)

(2,640)

(901)

Depreciation and amortization

260

245

518

672

EBITDA

(6,159)

(1,200)

(8,120)

(2,318)

Stock-based compensation

249

327

572

607

Provision for option liability

(2)

(4)

(25)

(1)

Adjusted EBITDA

($ 5,912)

($ 877)

($ 7,573)

($ 1,712)

Disclaimer

Assure Holdings Corp. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 21:57:36 UTC.


© Publicnow 2022
All news about ASSURE HOLDINGS CORP.
09/29Assure to Attend Investor Conferences in October 2022
AQ
09/07Assure Holdings Corp. : Other Events (form 8-K)
AQ
09/07Benchmark Company Lowers Assure Holdings' Price Target to $4 From $6, Maintains Specula..
MT
08/24Assure Holdings Corp. Closes $6.2 Million Underwritten Public Offering of Common Stock
GL
08/24Assure Holdings Corp. : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/23Assure Holdings Further Strengthens Business Development Team with Hiring of Robynn Swe..
GL
08/22Wall Street Set for Losses as Rate Hike Fears Resurface Ahead of Jackson Hole
MT
08/22Top Premarket Decliners
MT
08/22Assure Holdings Prices Underwritten Public Offering of Common Stock
MT
08/22Assure Holdings Corp. Prices $6.2 Million Underwritten Public Offering of Common Stock
GL
More news
Analyst Recommendations on ASSURE HOLDINGS CORP.
More recommendations
Financials (USD)
Sales 2022 24,9 M - -
Net income 2022 -7,43 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,34x
Yield 2022 -
Capitalization 13,3 M 13,3 M -
Capi. / Sales 2022 0,53x
Capi. / Sales 2023 0,28x
Nbr of Employees 134
Free-Float 76,0%
Chart ASSURE HOLDINGS CORP.
Duration : Period :
Assure Holdings Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,72 $
Average target price 6,17 $
Spread / Average Target 756%
EPS Revisions
Managers and Directors
John Allen Farlinger Executive Chairman & Chief Executive Officer
John C. Price Chief Financial Officer
Jerod Powell Chief Information Officer
Stephanie Krouse Vice President-Clinical Operations
James Watt National Technologist Director